SECOS restructure to generate significant growth in bioplastic resin sales
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Sustainable and eco-friendly bioplastics developer SECOS Group Limited (ASX:SES) has completed a strategic review into its wholly owned subsidiary Stellar Films Australia (SFA).
The review into the SFA division, which produces traditional plastic films, comes as the company executes its strategy to be a world leader in bioplastics.
In light of the review, SECOS has resolved to continue the transfer of SFA customers to its Malaysian operations and commence the orderly cessation of its Australian film manufacturing operations.
This decision to transfer SFA customers to its Malaysian operations is anticipated to achieve significant operating and overhead cost savings. Once the transition period has passed, SECOS expects to achieve an improvement to net profit after tax (NPAT) of more than $0.9 million per annum.
The review was undertaken by independent consultant Promentor, whose findings confirmed the Board’s expectation that SECOS can achieve significant operating and overhead cost savings by moving its current traditional plastic film production from its facility in Melbourne to its production facilities in Malaysia.
The decision will see SECOS incur a one-off cash charge of $0.9 million in FY19 which will be funded from the company’s recently completed share placement and rights issue. SECOS notes that the significant ongoing costs of keeping SFA open under its existing structure mean shareholders’ best interests will be served by taking this action immediately.
The review also determined that SECOS can improve profitability by ceasing to operate the SFA business, although the level of improvement will depend on how much business can be successfully transferred to the company’s Malaysian operations.
As such, at this stage the company will continue with its existing plans to transfer SFA customers to its Malaysian operations and will commence the orderly cessation of its Australian film manufacturing operations. It does expect most Australian customers to transfer their business to the company’s Malaysian operations.
SECOS has an established blue-chip traditional hygiene film customer base in its Malaysian operations with a unique opportunity to transition them to bioplastic (compostable and biohybrid) film sales.
SECOS Executive Chairman, Richard Tegoni, said, “The decision by the Board to cease operations in Australia is an important step to further lower SECOS Group’s cost base and to consolidate and optimise its manufacturing assets.
“With this improved structure, we expect to continue to deliver significant growth in bioplastic resin sales, and over time upgrade our world-class hygiene film production to support compostable and breathable film for the large and attractive feminine and infant hygiene markets.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.